Posted by Michael Wonder on 25 Jul 2025
Cabometyx approved in the EU for previously treated advanced neuroendocrine tumours
24 July 2025 - Approval based on pivotal CABINET Phase 3 trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumours, respectively.
Ipsen announced today that the European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic and extra-pancreatic neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.
